Latest Nanotechnology News

Dotz Nano Limited has raised approximately A$2 million through a private placement, reinforcing its position in the emerging carbon capture market with fresh capital and new investors.

Dotz Nano has extended the maturity dates of key convertible notes held by Mercer Street Capital Partners, signaling sustained investor confidence in its carbon capture technology and growth plans.

Nexsen Limited has successfully completed an $8 million IPO and ASX listing, while advancing its kidney diagnostic tests and initiating clinical trials for its GBS Rapid Sensor targeting expedited FDA approval.

Adisyn Ltd has strengthened its position in semiconductor innovation by commissioning a cutting-edge Atomic Layer Deposition system, accelerating its graphene interconnect development while maintaining a robust cash reserve.

Dotz Nano Limited has raised an additional A$460,000 through unsecured loans, bringing total funding under this facility to A$1.2 million to support working capital needs.

Dotz Nano has secured its first commercial order for its innovative Amine-Modified Polymer CO2 sorbent from a leading automotive innovation hub, marking a key step toward commercial deployment in sustainable aviation fuel production.

Dotz Nano Limited has raised approximately A$740,000 through unsecured loans featuring convertible options, aiming to bolster its working capital amid ongoing funding efforts.

Dotz Nano has responded to an ASX price query following unusual trading activity, confirming no undisclosed information and reaffirming compliance with continuous disclosure rules.

Dotz Nano Limited reported a reduced half-year loss and significant progress in its Direct Air Capture technology, while navigating funding uncertainties with key investors.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Locksley Resources has partnered with Rice University to pioneer domestic antimony processing in the US, aiming to reduce reliance on foreign supply and support critical defense and energy sectors.

Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.